Lack of germline mutations in the preproglucagon gene region coding for glucagon-like peptide 1 in Type 2 diabetic (NIDDM) patients

Experimental and Clinical Endocrinology and Diabetes

Volumn 108, Issue 2, 2000, Pages 72-75

  Nauck, M ^a   Hahn, S ^a   Sauerwald, A ^a   Schmiegel, W ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Gastric inhibitory polypeptide (GIP); Genetics; Glucagon like peptide 1 (GLP 1); Incretin; Insulin secretion; Type 2 diabetes

Indexed keywords

DNA; GLUCAGON LIKE PEPTIDE 1; PREPROGLUCAGON; RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EXON; FEMALE; FOOD INTAKE; GENE MUTATION; GERM LINE; HUMAN; LEUKOCYTE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SEQUENCE ANALYSIS;

AGED; AMINO ACID SEQUENCE; BASE SEQUENCE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDE FRAGMENTS; PROGLUCAGON; PROTEIN PRECURSORS; SEQUENCE ANALYSIS, DNA;

EID: 0034054153     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-5798     Document Type: Article

References (27)

1. Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC: Exon duplication and divergence in the human preproglucagon gene. Nature 304: 368-371, 1983
2. Cox NJ, Xiang K-S, Fajans S: Bell GI: Mapping diabetes-susceptibility genes. Lessons learned from search for DNA marker for maturity-onset diabetes of the young. Diabetes 41: 401-407, 1992
3. Fehmann HC, Gherzi R, Göke B: Regulation of islet hormone gene expression by incretin hormones. Exp Clin Endocrinol Diabetes 103 Suppl 2: 56-65, 1995
4. Gutniak MK, Holst JJ, Ørskov C, Åhren B, Efendic S: Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med. 326: 1316-1322, 1992
5. Holst JJ, Orskov C, Vagn-Nielsen O, Schwartz TW: Truncated glucagon-like peptide 1, an insulin-releasing hormone from the distal gut. FEBS Letters. 211: 169-174, 1987
6. Kolligs F, Fehmann HC, Göke R, Göke B: Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 44: 16-19, 1995
7. Komatsu R, Matsuyama T, Namba M et al.: Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide. Diabetes 38: 902-905, 1989
8. Kreymann B, Williams G, Ghatei MA, Bloom SR: Glucagon-like peptide-1 [7-36]: a physiological incretin in man. Lancet 2: 1300-1304, 1987
9. Mojsov S, Weir GC, Habener JF: Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 79: 616-619, 1987
10. Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF: Insulinotropic action of glucagon-like peptide 1 (7-37) in diabetic and non-diabetic subjects. Diabetes Care 15: 270-276, 1992
11. Nauck MA, Bartels E, Ørskov C, Ebert R, Creutzfeldt W: Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76: 912-917, 1993a
12. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W: Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91: 301-307, 1993b
13. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W: Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36: 741-744, 1993c
14. Nauck MA, Niedereichholz U, Ettler R et al.: Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 273: E981-988, 1997
15. Ørskov C: Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 35: 701-711, 1992
16. Ørskov C, Holst JJ, Nielsen OV: Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 123: 2009-2013, 1988
17. Ørskov C, Jeppesen J, Madsbad S, Holst JJ: Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 87: 415-423, 1991
18. Ørskov C, Knuhtsen S, Baldissera FG, Poulsen SS, Nielsen OV, Holst JJ: Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology 119: 1467-1475, 1986
19. Sauerwald A, Hahn S, Schmiegel W, Nauck M: Fehlen von Mutationen im Proglucagon-Exon, das für GLP-1 codiert, bei Patienten mit Typ II-Diabetes. Diabetes Stoffw. 6 (Suppl. 1): 97, 1997
20. Stoffel M, Espinosa Rd, Le Beau MM, Bell GI: Human glucagon-like peptide-1 receptor gene. Localization to chromosome band 6p21 by fluorescence in situ hybridization and linkage of a highly polymorphic simple tandem repeat DNA polymorphism to other markers on chromosome 6. Diabetes 42: 1215-1218, 1993
21. Turner RC, Hattersley AT, Shaw JTE, Levy JC: Type II diabetes: Clinical aspacts of molecular biological studies. Diabetes 44: 1-10, 1995
22. Turton MD, O'Shea D, Gunn I et al.: A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379: 69-72, 1996
23. Valverde I, Villanueva Penacarrillo ML: In vitro insulinomimetic effects of GLP-1 in liver, muscle and fat. Acta Physiol Scand. 157: 359-360, 1996
24. Vionnet N, Hani EH, Lesage S et al.: Genetics of NIDDM in France. Studies with 19 candidate genes in affected sib pairs. Diabetes 46: 1062-1068, 1997
25. Walsh PS, Metzger DA, Higuchi R: Chelex 100 as a medium for simple extraction of DNA for PCR-based typing from forensic material. BioTechniques 10: 506-513, 1991
26. Wang Z, Wang RM, Owji AA, Smith DM, Ghatei MA, Bloom SR: Glucagon-like peptide-1 is a physiological incretin in rat. J Clin Invest. 95:417-421, 1995
27. Willms B, Werner J, Holst JJ, Ørskov C, Creutzfeldt W, Nauck MA: Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab. 81: 327-332, 1996